Reproductive · Year 2 · from Reproductive
Case 1: Menopausal Vasomotor Symptoms and Hormone Therapy
Clinical Image
Source: Wikipedia - Menopause - CC BY-SA 4.0
Case Presentation
A 52-year-old woman presents with severe hot flashes that have significantly impacted her quality of life for the past year. She reports 10-12 hot flashes daily, each lasting 2-4 minutes, accompanied by profuse sweating and palpitations. Night sweats wake her 3-4 times nightly, causing chronic sleep deprivation. Her last menstrual period was 14 months ago. She has tried lifestyle modifications including keeping the room cool, wearing layers, avoiding triggers (alcohol, spicy foods), and taking black cohosh supplements without improvement. Her medical history is unremarkable with no history of VTE, cardiovascular disease, or breast cancer. Family history is negative for breast cancer. BMI is 24, and she does not smoke. Physical examination is normal. Based on her age and 12+ months of amenorrhea, she is diagnosed with menopause; laboratory testing is not required. Given her severe symptoms affecting quality of life, no contraindications to hormone therapy, and timing within 10 years of menopause onset (favorable per the "timing hypothesis"), she is started on transdermal estradiol 0.05 mg patch twice weekly plus oral micronized progesterone 200 mg for 12 days per month for endometrial protection. At 8-week follow-up, her hot flashes have decreased by 80%, sleep has improved dramatically, and she reports significantly better quality of life.
Key Learning Points
- Vasomotor symptoms (hot flashes and night sweats) affect 75-80% of women during the menopausal transition and persist for a median of 7-10 years
- Hormone therapy is the most effective treatment for vasomotor symptoms, reducing hot flash frequency by approximately 75%
- The "timing hypothesis" supports initiating HT within 10 years of menopause or before age 60, when cardiovascular benefits may outweigh risks
- Women with an intact uterus require progestogen (progesterone or progestin) to prevent endometrial hyperplasia from unopposed estrogen; micronized progesterone has favorable lipid and sleep-promoting effects